Skip to main
BMEA

BMEA Stock Forecast & Price Target

BMEA Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Biomea Fusion is well-positioned to capture a significant chunk of the diabetic treatment market with its innovative and potentially game-changing drug candidate icovamenib. The company also has a strong pipeline, with BMF-650 showing promise as a potential treatment for obesity, providing additional growth opportunities. Strong clinical data and upcoming catalysts make Biomea Fusion a company to watch in the pharmaceutical industry.

Bears say

Biomea Fusion is a clinical-stage company that is heavily reliant on the success of its two core drug candidates, icovamenib and BMF-650, which both target diabetes and obesity. However, the company has a history of operating losses and faces significant financial risks, including the possibility of dilutive capital raises. Additionally, while icovamenib has shown promising results in early trials, it still has a long development path ahead and faces competition from other menin inhibitors. Overall, the company's current outlook is negative due to uncertainty surrounding its drug candidates and financial stability.

BMEA has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Biomea Fusion Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Biomea Fusion Inc (BMEA) Forecast

Analysts have given BMEA a Strong Buy based on their latest research and market trends.

According to 3 analysts, BMEA has a Strong Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Biomea Fusion Inc (BMEA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.